TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10972662

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (1.5 mg/m2 body surface area)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (1.5 mg/m2 body surface area)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control values for Sr absorption (separate group of children with CRF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol and Oral calcitriol
Number of subjects: 20
Study: 9076452

Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 183
Study: 8439828

Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine initial dose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg nitrendipine twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine once daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic nitrendipine therapy
Number of subjects: 16
Study: 3301560

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg/die for patients <70 kg; 15 mg/die for patients >70 kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30200895

Group type: EXPERIMENTAL
Intervention: Standard prednisolone plus high-dose mizoribine (10 mg/kg/day once daily for 2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard prednisolone alone
Number of subjects: 0
Study: 27456976

Group type: EXPERIMENTAL
Intervention: Guided self-help CBTv (12-week intervention with eight therapist support sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait list control condition
Number of subjects: 30
Study: 23918230

Group type: EXPERIMENTAL
Intervention: Justice violation condition (experimenter negligence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (standard protocol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negligence/justice violation condition
Number of subjects: 0
Study: 21740624

Group type: EXPERIMENTAL
Intervention: Self-help programme with extensive email support
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Self-help programme with minimal email support
Number of subjects: 376

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 376
Study: 20204925

Group type: EXPERIMENTAL
Intervention: Hypothetical with CE (HE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypothetical (H)
Number of subjects: 0
Study: 18378568

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 15709986

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11833025

Group type: EXPERIMENTAL
Intervention: Dual tasks (simultaneous cognitive tasks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Single tasks (motor and cognitive performances)
Number of subjects: 23
Study: 10341672

Group type: EXPERIMENTAL
Intervention: Low-fat meal (0.2 g/kg body weight; mean 14 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat meal (0.6 g/kg body weight; mean 43 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both meals (Low-fat and High-fat)
Number of subjects: 0
Study: 7776772

Group type: COMPARATOR
Intervention: Radiotherapy alone (three fractions of 8 Gy or 9 Gy in 8 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by hyperthermia (43 degrees C for 60 min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Radiation dose of 24 Gy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Radiation dose of 27 Gy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tumour size ≤ 4 cm
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tumour size > 4 cm
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall 5-year survival rate
Number of subjects: 70
Study: 2261306

Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diatrizoate
Number of subjects: 100
Study: 371597

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol maleate 1.0%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30844995

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring use with counseling and social support intervention
Number of subjects: 2585

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring use without worries
Number of subjects: 2585

Group type: COMPARATOR
Intervention: Dapivirine vaginal ring use after intervention
Number of subjects: 2585
Study: 28756438

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 26209502

Group type: COMPARATOR
Intervention: AS + RT
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: AS + RT + CT
Number of subjects: 397
Study: 24327333

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FAC (fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Neoadjuvant CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Neoadjuvant FAC
Number of subjects: 126

Group type: COMPARATOR
Intervention: Neoadjuvant CMF
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both regimens (FAC and CMF)
Number of subjects: 126

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Number of pathologically involved lymph nodes (pLN)
Number of subjects: 126
Study: 23014489

Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) foods (80 g/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Refined-grain (RG) foods (0 g/d)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both WG and RG foods
Number of subjects: 83
Study: 19954479

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) twice a week for a total of ten treatments, along with high-dose supplementation of zinc and vitamins A, E, and beta-carotene.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) after the fifth treatment.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment (RT) compared to before RT at time 1 and time 2.
Number of subjects: 7
Study: 17678776

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with propofol target-controlled infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil with propofol target-controlled infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-dose remifentanil with propofol target-controlled infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose remifentanil with propofol target-controlled infusion
Number of subjects: 60
Study: 15181127

Group type: COMPARATOR
Intervention: (99m)Tc-ECD SPECT in IPD patients
Number of subjects: 140

Group type: COMPARATOR
Intervention: (99m)Tc-ECD SPECT in MSA patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Dopamine agonist dosage in PD patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Cognitive performance in relation to limbic perfusion
Number of subjects: 140
Study: 11813898

Group type: EXPERIMENTAL
Intervention: Plateau time of 1 ms
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plateau time of 2 ms
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plateau time of 5 ms
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Plateau time of 10 ms
Number of subjects: 26
Study: 9264355

Group type: EXPERIMENTAL
Intervention: Luteal phase mammograms in women who ever used estrogen
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Follicular phase mammograms in women who ever used estrogen
Number of subjects: 8887

Group type: EXPERIMENTAL
Intervention: Luteal phase mammograms in never-users of estrogen
Number of subjects: 8887

Group type: COMPARATOR
Intervention: Follicular phase mammograms in never-users of estrogen
Number of subjects: 8887
Study: 8510911

Group type: EXPERIMENTAL
Intervention: FASTPAC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard full-threshold 4-2-dB double-staircase strategy
Number of subjects: 30
Study: 3481318

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg (twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg (twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg (twice daily)
Number of subjects: 12
Study: 30202041

Group type: EXPERIMENTAL
Intervention: Multidimensional hierarchical mixture models for SNP analysis
Number of subjects: 0
Study: 30102787

Group type: EXPERIMENTAL
Intervention: Self-compassionate letter-writing intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 40
Study: 27184586

Group type: EXPERIMENTAL
Intervention: Dedicated self-expanding Axxess™ biolimus-eluting bifurcation stent in the proximal main vessel and additional Absorb™ everolimus-eluting BRS in the branches
Number of subjects: 60

Group type: COMPARATOR
Intervention: Modified T technique using Absorb™ only
Number of subjects: 60
Study: 24701541

Group type: EXPERIMENTAL
Intervention: Titanium microimplants (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional molar anchorage (Group B)
Number of subjects: 20
Study: 22342916

Group type: EXPERIMENTAL
Intervention: HBsAg-1018 ISS vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Engerix-B(®) (licensed hepatitis B vaccine)
Number of subjects: 0
Study: 21047593

Group type: EXPERIMENTAL
Intervention: Serum PSA screening with a cut-off of 4 ng/ml
Number of subjects: 56294

Group type: EXPERIMENTAL
Intervention: Serum PSA screening with a cut-off of 3 ng/ml
Number of subjects: 56294

Group type: EXPERIMENTAL
Intervention: Advanced prostate cancer detection
Number of subjects: 56294

Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 56294

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 56294
Study: 17548243

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg once per day
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 16262574

Group type: EXPERIMENTAL
Intervention: Laser treatment with exercise protocol for 10 sessions over 2 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo laser treatment with exercise protocol for 10 sessions over 2 weeks.
Number of subjects: 40
Study: 11905448

Group type: EXPERIMENTAL
Intervention: Dental auscultation and traditional oral health care education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional oral health care education
Number of subjects: 0
Study: 10069683

Group type: EXPERIMENTAL
Intervention: Xamoterol (100 mg, p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg, p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg, p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Celiprolol (600 mg, p.o.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Celiprolol (1,200 mg, p.o.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bisoprolol (control for xamoterol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Celiprolol (after terbutaline treatment)
Number of subjects: 6
Study: 7567313

Group type: EXPERIMENTAL
Intervention: Ceftibuten suspension (9 mg/kg once daily, max 400 mg)
Number of subjects: 1312
Study: 1967592

Group type: EXPERIMENTAL
Intervention: Intravenous fenoldopam mesylate, infused at a maximal dose increment of 0.2 microgram/kg/min, with a maximal infusion rate of 1.5 micrograms/kg/min.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside, infused at a maximal dose increment of 1 microgram/kg/min, with a maximal infusion rate of 8 micrograms/kg/min.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (fenoldopam and nitroprusside)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 0
Study: 7387812

Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during untreated condition (n=29)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during treatment with propranolol (320 mg/day) (n=15)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during treatment with propranolol plus atropine (0.04 mg/kg) (n=12)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during propranolol (n=15)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Diazoxide (300 mg i.v.) without propranolol (n=15)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Diazoxide (300 mg i.v.) during propranolol plus atropine (n=12)
Number of subjects: 41
Study: 30586728

Group type: EXPERIMENTAL
Intervention: U-IR (LV unloading followed by immediate reperfusion)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: U-DR (LV unloading followed by delayed reperfusion after 30 minutes)
Number of subjects: 50

Group type: COMPARATOR
Intervention: U-IR
Number of subjects: 50

Group type: COMPARATOR
Intervention: U-DR
Number of subjects: 50
Study: 28786854

Group type: EXPERIMENTAL
Intervention: T‐ScEmo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cogniplus
Number of subjects: 61
Study: 25517261

Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patch (Durogesic® D-TRANS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23640130

Group type: EXPERIMENTAL
Intervention: Implementation intention imagery
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Arousal reduction imagery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control imagery
Number of subjects: 104
Study: 21177798

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern (≤20% of total energy)
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 1580
Study: 18581064

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein-2 (rhBMP-2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Autogenous bone
Number of subjects: 11
Study: 17714461

Group type: EXPERIMENTAL
Intervention: Planning Ahead Together (PAT) document, a research advance directive (n=69)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (n=80)
Number of subjects: 149
Study: 15121552

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Crossover to Hysterectomy
Number of subjects: 63
Study: 11843850

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9793698

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 7848930

Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (MSO4) via continuous infusion (initial bolus of 0.03 mg/kg, infusion of 0.01% morphine at 5 mL/hour, titrated from 0.2 to 1.0 mg/hour)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural morphine sulfate (MSO4) via intermittent bolus (initial bolus of 0.07 mg/kg, followed by 2-5 mg on demand)
Number of subjects: 30
Study: 3907037

Group type: EXPERIMENTAL
Intervention: High fluid replacement (total volume of urine output + 30 ml/hr)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low fluid replacement (constant 125 ml/hr)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (High and Low fluid replacement)
Number of subjects: 14
Study: 31397718

Group type: EXPERIMENTAL
Intervention: Paraprofessional home visiting intervention (n = 644)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Standard care condition (n = 594)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Home visiting intervention
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Maternal breastfeeding for at least 3 months
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Attending a preschool crèche
Number of subjects: 1238
Study: 29166769

Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention (n = 301)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Standard care (n = 310)
Number of subjects: 611
Study: 27244204

Group type: EXPERIMENTAL
Intervention: Supine position technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 40
Study: 24684771

Group type: EXPERIMENTAL
Intervention: PRT‐201 at 10 μg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PRT‐201 at 30 μg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PRT‐201 at 10 μg (RCF subset)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: PRT‐201 at 30 μg (RCF subset)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (RCF subset)
Number of subjects: 151
Study: 22525444

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (nasal prongs, 1-2 L/min flow)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 58
Study: 19837146

Group type: EXPERIMENTAL
Intervention: US(1) (2.72 W/cm(2))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: US(2) (3.50 W/cm(2))
Number of subjects: 10

Group type: COMPARATOR
Intervention: No US
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: US(1) and US(2)
Number of subjects: 10
Study: 17663099

Group type: EXPERIMENTAL
Intervention: Drug-separated moxibustion at the navel
Number of subjects: 71

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 71

Group type: COMPARATOR
Intervention: Western medicine (vitamin E capsules, 0.1 g twice daily)
Number of subjects: 71
Study: 17470188

Group type: EXPERIMENTAL
Intervention: Diabetes self-management program
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 147
Study: 14997748

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (Als)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate markers in neo-adjuvant endocrine treatment
Number of subjects: 0
Study: 11126208

Group type: EXPERIMENTAL
Intervention: Caffeine/Ephedrine (CE) mixture (100 mg/10 mg for those <80 kg, 200 mg/20 mg for those >80 kg, taken three times daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 32
Study: 8694951

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal hernioplasty
Number of subjects: 87

Group type: COMPARATOR
Intervention: Shouldice herniorrhaphy
Number of subjects: 87
Study: 1571917

Group type: EXPERIMENTAL
Intervention: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at HIGH dose rate (15 cGy/min)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at LOW dose rate (6 cGy/min)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at HIGH dose rate (6 cGy/min)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at LOW dose rate (3 cGy/min)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Single-dose HIGH instantaneous dose rate TBI
Number of subjects: 157
Study: 2989346

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice with soluble pyrophosphates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice without soluble pyrophosphates (control)
Number of subjects: 0
Study: 30647034

Group type: EXPERIMENTAL
Intervention: Cardiac output-guided fluid therapy with low-dose inotrope infusion
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2502
Study: 26104031

Group type: EXPERIMENTAL
Intervention: Exercise park intervention group (EPIG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 120
Study: 24217699

Group type: EXPERIMENTAL
Intervention: Nitroxoline (NTX) at 250 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Trimethoprim (TMP) at 200 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroxoline (NTX) at 250 mg three times a day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TMP-resistant Escherichia coli strain
Number of subjects: 6
Study: 21849554

Group type: EXPERIMENTAL
Intervention: Theta-burst transcranial magnetic stimulation (TBS) targeting the posterior medial frontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimulation over another brain area
Number of subjects: 0
Study: 19826023

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 1400
Study: 17643389

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 95
Study: 15006907

Group type: COMPARATOR
Intervention: Modified invitation letter
Number of subjects: 12240

Group type: EXPERIMENTAL
Intervention: Reminder letter
Number of subjects: 12240

Group type: EXPERIMENTAL
Intervention: Phone reminder
Number of subjects: 12240

Group type: EXPERIMENTAL
Intervention: Combinations of modified invitation, written reminder, and phone reminder
Number of subjects: 12240
Study: 11306208

Group type: EXPERIMENTAL
Intervention: Transdermal gel (1.0 mg estradiol daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transdermal patch (50 microg/24 h)
Number of subjects: 24
Study: 9336557

Group type: EXPERIMENTAL
Intervention: 200 mg/day of Panax ginseng C.A. Meyer (G115)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 400 mg/day of Panax ginseng C.A. Meyer (G115)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 7953885

Group type: EXPERIMENTAL
Intervention: Employed women
Number of subjects: 121
Study: 3680579

Group type: EXPERIMENTAL
Intervention: Acute withdrawal from cigarette smoking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control conditions (smoking)
Number of subjects: 24